India has approved its first midazolam nasal spray. CDSCO granted New Drug Permission to Biodeal Pharmaceuticals for an indigenously developed Midazolam Nasal Spray 1.25% w/v on 5 May 2025 — the first approval of this product and this strength in the country. On top of that, NPPA’s Multidisciplinary Committee of Experts has recommended a five-year exemption from price control under Para 32(iii) of the DPCO, 2013, treating the product as a genuinely new, indigenously developed delivery system rather than a reformulation of an existing medicine.
The two decisions — a regulatory approval and a pricing carve-out — were announced together by the company on 12 November 2026 and reported across Express Pharma, BioSpectrum India, Pharmabiz, BW Healthcare World and ETPharma. For importers and buyers of Indian generics, this is a useful case study in how India separates what a drug is from what it may cost.
💉 What Was Actually Approved
Biodeal Pharmaceuticals is a Noida-headquartered contract development and manufacturing organisation (CDMO) whose flagship capability is intranasal drug delivery. The approved product is a 1.25% w/v midazolam nasal spray, developed primarily at the company’s DSIR-accredited R&D facility — DSIR accreditation being the Department of Scientific and Industrial Research recognition that underpins in-house R&D claims for Indian manufacturers.
Midazolam is a well-established medicine used for rapid management of medical emergencies, principally acute seizures. It has historically been given by injection. The nasal route matters most in emergency and out-of-hospital settings, where intravenous access may not be readily available — a paramedic or caregiver cannot start a line in a convulsing patient, but can administer a nasal spray.
- Product: Midazolam Nasal Spray 1.25% w/v
- Approval: New Drug Permission from CDSCO, dated 5 May 2025
- First-of-kind: No other strength of midazolam nasal spray had been approved by CDSCO before this
- Manufacturer: Biodeal Pharmaceuticals Ltd., Noida (WHO-GMP and PIC/S certified CDMO)
- Pricing status: NPPA MDC recommendation for five-year DPCO exemption under Para 32(iii)
📜 The Para 32(iii) Exemption — Read It Precisely
Most coverage summarises the exemption in one line. The statutory text is more specific, and the wording is what determines whether a product qualifies. Para 32 of the DPCO, 2013 states that the Order “shall not apply to”:
“(iii) a manufacturer producing a new drug involving a new delivery system developed through indigenous Research and Development for a period of five years from the date of its market approval in India: Provided that the provision of this paragraph shall apply only when a document showing approval of such new drugs from Drugs Controller General (India) is produced before the Government.”
Three conditions must all be satisfied:
- It must be a “new drug” — and the Explanation to Para 32 pins that term to Rule 122E of the Drugs and Cosmetics Rules, 1945, not to the DPCO’s own general definition in Para 2(u). This matters: the two definitions are not identical, and using the wrong one is a common source of confusion.
- It must involve a new delivery system developed through indigenous R&D — a reformulation does not qualify.
- DGCI approval must be on paper before the Government. The proviso makes the approval document a condition precedent, not a formality.
The five years run from the date of market approval in India — which is 5 May 2025 in this case — not from the date of commercial launch, and not from the date NPPA decides. That distinction is worth noting for anyone modelling the timeline.
🔍 Why the Exemption Took Five Meetings to Decide
This was not a rubber-stamp. The NPPA record — as reported by Medical Dialogues on 6 October 2025 — shows the application being examined across multiple sittings of the Multidisciplinary Committee of Experts:
- 68th MDC (3 June 2025) and 69th MDC (3 July 2025): first deliberations. In the 69th, the Committee told the applicant to submit documents substantiating the claim of a novel drug delivery system developed through indigenous R&D.
- 22 July 2025: the company submitted minutes of the SEC (Neurology & Psychiatry) meeting of 18 April 2024, arguing that while tablet and parenteral forms of midazolam were already approved, the intranasal route had not been approved by CDSCO until its own permission — which is what establishes novelty of the delivery system.
- 28 July 2025: NPPA sought input from the Office of CDSCO. CDSCO replied on 1 August 2025 confirming the New Drug permission was granted on 5 May 2025 and that midazolam nasal spray 1.25% w/v “was not approved by this office” earlier.
- 70th MDC (5 August 2025): further clarification sought; the applicant directed to appear in person with product development documentation.
- 71st MDC (16 September 2025): after the company presented on formulation development and the delivery mechanism, and after the O/o DCGI wrote again on 11 September 2025 reiterating that only the 1.25% w/v strength had been approved, the Committee recommended obtaining views from the Standing National Committee on Medicines (SNCM) and CDSCO on one loose end: midazolam nasal spray appears in the National List of Essential Medicines (NLEM), 2022.
That last point is the genuinely interesting wrinkle for policy watchers. NPPA had already notified a ceiling price for the applied formulation, based on market data in which three companies appeared to be manufacturing or marketing it. The Committee therefore wanted SNCM and CDSCO to reconcile two things: an essential-medicines listing premised on the medicine being approved and licensed in India, versus a product that no Indian regulator had approved before May 2025.
The eventual recommendation recognises the product as “a genuinely new, indigenously developed drug delivery system rather than a reformulation of an existing medicine” — the exact distinction Para 32(iii) is built around.
🌍 The US Precedent — and What It Tells You
Nasal midazolam is not an Indian invention in the abstract. The route was pioneered commercially in the United States, where the FDA approved Nayzilam (midazolam) nasal spray on 20 May 2019 for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity — seizure clusters — in patients with epilepsy, developed by UCB. Biodeal’s own announcement acknowledges that the nasal route is “a new well established delivery system innovated in the US.”
For a buyer, this is the right way to read “first in India” claims. It means first within the Indian regulatory jurisdiction, which is a real achievement for indigenous development and device engineering — not a world-first therapeutic innovation. Reporting the two as the same thing is a common press-release inflation.
🧾 What the Price Exemption Does and Does Not Mean
A five-year Para 32(iii) exemption means the DPCO does not apply to this formulation for that window. In practice:
- No ceiling price is fixed for the exempt product during the five years.
- The manufacturer is not bound by the non-scheduled 10% annual increase cap under Para 20 for that product either — the whole Order is disapplied, not just the ceiling mechanism.
- It is not a subsidy, and it does not guarantee availability or affordability. An exempt product can be priced at whatever the market bears. Buyers should not read “price exemption” as “cheaper.”
- It is time-limited and product-specific. The protection attaches to this formulation and strength, not to midazolam as a molecule, and not to the company’s other products.
- Other forms remain under control. Injectable and tablet midazolam are unaffected — their pricing status is unchanged by this decision.
The policy logic is straightforward: the DPCO deliberately buys innovation with a temporary pricing holiday. Para 32 exists so that a company spending years on device engineering and dosing precision is not immediately forced onto a ceiling derived from older dosage forms. Whether five years is the right length is a legitimate debate — but the mechanism is intentional, not a loophole.
✅ How Buyers and Importers Should Verify Claims Like This
Announcement-driven approvals are exactly where sourcing discipline pays off. A practical checklist:
- Separate the two approvals. A CDSCO New Drug Permission and an NPPA pricing recommendation are different instruments from different regulators. Ask for both, in writing, and check the dates independently.
- Check the strength matters. Novelty here rested on 1.25% w/v only. A claim covering “midazolam nasal spray” generally is broader than the permission granted.
- Confirm what is exempted and from when. Para 32(iii) runs from market approval, and applies to a specific formulation. It is not a licence-wide or company-wide status.
- Distinguish “first in India” from “first globally.” The first is verifiable against CDSCO records; the second usually is not true.
- Verify the manufacturer’s facility credentials — WHO-GMP and PIC/S certification, and the specific site cleared for the dosage form, not just the corporate group.
- Do not infer clinical superiority. A new route of administration improves practical deliverability in emergency settings. It is not by itself evidence of better outcomes than intravenous midazolam where IV access exists.
For a list of verified and reliable pharmaceutical distributors, refer to the IMSDA’s verified member directory.
📌 The Bottom Line
India now has a domestically developed midazolam nasal spray, approved at a single strength, with a five-year pricing holiday granted on the strength of a delivery-system novelty argument that NPPA tested across five committee sittings and two CDSCO clarifications. That process — evidence submitted, regulator consulted, loose ends referred to SNCM — is the part worth trusting. It is a real, if narrow, win for Indian R&D in complex drug-device products.
The caution is equally real: “first in India” is a jurisdictional claim, “price exemption” is not a price cut, and the DPCO will reapply to this formulation after five years from 5 May 2025 unless extended or the product is brought into the scheduled list.
Sources: Express Pharma, “Biodeal Pharmaceuticals receives CDSCO approval for Midazolam nasal spray,” 12 November 2026; BioSpectrum India, “Biodeal Pharma receives New Drug Permission from CDSCO for indigenously developed Midazolam Nasal Spray,” 12 November 2026; Pharmabiz, “Biodeal Pharmaceuticals marks R&D milestone with India’s first approved Midazolam Nasal Spray,” 12 November 2026; BW Healthcare World, 16 November 2026; ETPharma, “Biodeal Pharma gets DCGI nod for midazolam nasal spray,” 14 November 2026; Medical Dialogues, “Price Cap Exemption Pending: NPPA Refers Biodeal Pharma’s Midazolam Nasal Spray to CDSCO, SNCM for Review,” 6 October 2025; NPPA, Drugs (Prices Control) Order, 2013 (S.O. 1221(E) dated 15 May 2013, as amended) — Para 32(iii) quoted verbatim; US FDA approval of Nayzilam (midazolam) nasal spray, 20 May 2019.
For more information, contact IMSDA at contact@indiamedicine.org.
